Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.
Journal: Annals of clinical and translational neurology
Published: December 26, 2025
Epstein-Barr virus and multiple sclerosis: A mechanism comes into focus.
Journal: Multiple sclerosis and related disorders
Published: October 23, 2025
Intranasal sensitization model of alopecia areata using pertussis toxin as adjuvant.
Journal: Frontiers in immunology
Published: July 23, 2024
Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 08, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
Journal: Multiple sclerosis and related disorders
Published: October 11, 2023
Trigeminal neuralgia in multiple sclerosis: Association with demyelination and progression.
Journal: Multiple sclerosis and related disorders
Published: February 08, 2023
The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment.
Journal: Multiple sclerosis and related disorders
Published: October 20, 2022
Progressive Optic Neuropathy in Cerebellar Ataxia, Areflexia, Optic Atrophy, and Sensorineural Hearing Loss Syndrome: The Importance of Targeted Gene Testing.
Journal: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
Published: October 03, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 30, 2022
Brain Antigens Stimulate Proliferation of T Lymphocytes With a Pathogenic Phenotype in Multiple Sclerosis Patients.
Journal: Frontiers in immunology
Published: December 14, 2021
The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment.
Journal: Multiple sclerosis and related disorders
Published: June 12, 2021
Last Updated: 09/26/2026